EUVIMEDEUVIMED entdecken
Crossref

Development and Synthesis of Bioactive (3‐Arylediene‐1‐phenyl‐1 H ‐pyrazol‐4‐yl)acryloyl‐4‐hydroxy‐6‐methyl‐2 H ‐pyran‐2‐ones With Anti‐Malarial and Anti‐Inflammatory Activities

Priyanka Rani iD, Sudeep Dhillon, Ginna Kumari, Mamta Chahal, Binesh Kumar iD, Jai Devi, Deepak Kumar Aneja iD, Mayank Kinger iD

Archiv der Pharmazie · 2026-04 · 359 (4)

DOI: 10.1002/ardp.70231 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Archiv der Pharmazie, online erschienen am 08.04.2026. Verfasst von Priyanka Rani und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, Chaudhary Bansi Lal University, Bhiwani, Haryana, India. Hauptthemen laut MEDLINE: Antimalarials, Anti-Inflammatory Agents, Anti-Inflammatory Agents, Non-Steroidal, Pyrazoles. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 56 Literaturangaben. Gefördert von: University Grants Commission (UGC), India, Council of Scientific and Industrial Research (CSIR), India, Chaudhary Bansi Lal University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chalcones are versatile scaffolds with broad pharmacological relevance, particularly as anti‐inflammatory and anti‐malarial agents. In the current investigation, a series of (3‐arylediene‐1‐phenyl‐1 H ‐pyrazol‐4‐yl)acryloyl‐4‐hydroxy‐6‐methyl‐2 H ‐pyran‐2‐one analogs/1,3‐diarylprop‐2‐en‐1‐ones were successfully synthesized, leveraging dehydroacetic acid (DHA) as the precursor molecule. The choice of DHA is strategic as it is a bioactive and highly versatile scaffold bearing a 4‐hydroxy‐6‐methyl‐2 H ‐pyran‐2‐one moiety, which enhances structural diversity and provides multiple reactive sites for functionalization. Its inherent anti‐microbial, anti‐inflammatory, and anti‐malarial potential offers an added advantage over conventional precursors, thereby increasing the likelihood of generating pharmacologically active chalcone hybrids. The synthetic protocol employed in this study involved the implementation of a Claisen condensation reaction, wherein DHA was reacted with formyl pyrazole to afford the corresponding chalcones, with yields ranging from moderate to good. The synthesized compounds were subjected to a rigorous characterization protocol, involving a battery of analytical techniques, including 1 H‐NMR, 13 C‐NMR, FT‐IR, and HRMS analyses. Biological evaluation focused on anti‐malarial and anti‐inflammatory activities, while molecular docking (PyRx 0.8) was performed to explore binding interactions with cyclooxygenase‐2 (COX‐2; PDB ID: 3LN1) and enoyl‐acyl‐carrier‐protein reductase (EACPR; PDB ID: 1NHG). Notably, compound 3c emerged as the most potent one within the synthesized series, exhibiting remarkable anti‐inflammatory and anti‐malarial potency, as evidenced by its IC 50 values of 7.05 ± 0.17 µM and 0.95 ± 0.06 µM, respectively. Docking studies revealed strong binding affinities and favorable molecular interactions, supporting the observed bioactivities. This study highlights chalcone–pyrazole hybrids as promising therapeutic scaffolds. In particular, compound 3c emerges as a compelling lead candidate for further optimization and preclinical investigation as a dual‐action agent against malaria and inflammation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AntimalarialsAnti-Inflammatory AgentsAnti-Inflammatory Agents, Non-SteroidalPyrazolesStructure-Activity RelationshipAnimalsMolecular StructureMicePlasmodium falciparumMolecular Docking SimulationDrug DesignCyclooxygenase 2Dose-Response Relationship, Drug

Stichwörter der Autor:innen

anti‐inflammatoryanti‐malarialchalconedehydroacetic acidformypyrazolepyRx

Substanzen

AntimalarialsAnti-Inflammatory AgentsAnti-Inflammatory Agents, Non-SteroidalPyrazolesCyclooxygenase 2

Autor:innen und Institutionen

  • Department of Chemistry, Chaudhary Bansi Lal University, Bhiwani, Haryana, India.
  • Department of Chemistry, Guru Jambheshwar University of Science and Technology, Hisar, Haryana, India.

ORCID-Profile: Priyanka Rani, Binesh Kumar, Deepak Kumar Aneja, Mayank Kinger

Förderung

  • University Grants Commission (UGC), India
  • Council of Scientific and Industrial Research (CSIR), India
  • Chaudhary Bansi Lal University

Zitieren

APA

Rani, P., Dhillon, S., Kumari, G., Chahal, M., Kumar, B., Devi, J., Aneja, D. K., & Kinger, M. (2026). Development and Synthesis of Bioactive (3‐Arylediene‐1‐phenyl‐1 H ‐pyrazol‐4‐yl)acryloyl‐4‐hydroxy‐6‐methyl‐2 H ‐pyran‐2‐ones With Anti‐Malarial and Anti‐Inflammatory Activities. Archiv der Pharmazie, 359(4). https://doi.org/10.1002/ardp.70231

Vancouver

Rani P, Dhillon S, Kumari G, Chahal M, Kumar B, Devi J, et al. Development and Synthesis of Bioactive (3‐Arylediene‐1‐phenyl‐1 H ‐pyrazol‐4‐yl)acryloyl‐4‐hydroxy‐6‐methyl‐2 H ‐pyran‐2‐ones With Anti‐Malarial and Anti‐Inflammatory Activities. Archiv der Pharmazie. 2026;359(4). doi:10.1002/ardp.70231

BibTeX
@article{Rani2026,
  author = {Rani, Priyanka and Dhillon, Sudeep and Kumari, Ginna and Chahal, Mamta and Kumar, Binesh and Devi, Jai and Aneja, Deepak Kumar and Kinger, Mayank},
  title = {Development and Synthesis of Bioactive (3‐Arylediene‐1‐phenyl‐1 H ‐pyrazol‐4‐yl)acryloyl‐4‐hydroxy‐6‐methyl‐2 H ‐pyran‐2‐ones With Anti‐Malarial and Anti‐Inflammatory Activities},
  journal = {Archiv der Pharmazie},
  year = {2026},
  volume = {359},
  number = {4},
  doi = {10.1002/ardp.70231}
}
Kostenlos starten →